Saw palmetto extracts for treatment of benign prostatic hyperplasia - A systematic review

被引:237
作者
Wilt, TJ
Ishani, A
Stark, G
MacDonald, R
Lau, J
Mulrow, C
机构
[1] Vet Affairs Med Ctr, Dept Vet Affairs, Cochrane Collaborat Review Grp Prostat Dis & Urol, Coordinating Ctr, Minneapolis, MN 55417 USA
[2] Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis Vet Integrated Serv Network 13, Minneapolis, MN USA
[3] New England Med Ctr, Boston, MA 02111 USA
[4] Dept Vet Affairs, Cochrane Ctr, San Antonio, TX USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 280卷 / 18期
关键词
D O I
10.1001/jama.280.18.1604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To conduct a systematic review and, where possible, quantitative meta-analysis of the existing evidence regarding the therapeutic efficacy and safety of the saw palmetto plant extract, Serenoa repens, in men with symptomatic benign prostatic hyperplasia (BPH). Data Sources.-Studies were identified through the search of MEDLINE (1966-1997), EMBASE, Phytodok, the Cochrane Library, bibliographies of identified trials and review articles, and contact with relevant authors and drug companies, Study Selection.-Randomized trials were included if participants had symptomatic BPH, the intervention was a preparation of S repens alone or in combination with other phytotherapeutic agents, a control group received placebo or other pharmacological therapies for BPH, and the treatment duration was at least 30 days. Data Extraction.-Two investigators for each article (T.J.W,, A.I., G,S., and R.M.) independently extracted key data on design features, subject characteristics, therapy allocation, and outcomes of the studies. Data Synthesis.-A total of 18 randomized controlled trials involving 2939 men met inclusion criteria and were analyzed, Many studies did not report results in a method that permitted meta-analysis. Treatment allocation concealment was adequate in 9 studies; 16 were double-blinded. The mean study duration was 9 weeks (range, 4-48 weeks). As compared with men receiving placebo, men treated with S repens had decreased urinary tract symptom scores (weighted mean difference [WMD], -1.41 points [scale range, 0-19] [95% confidence interval (CI), -2.52 to -0.30] [n = 1 study]), nocturia (WMD, -0.76 times per evening [95% CI, -1.22 to -0.32] [n = 10 studies]), and improvement in self-rating of urinary tract symptoms; risk ratio for improvement (1.72 [:95% CI, 1.21-2.44] [n = 6 studies]), and peak urine flow (WMD, 1.93 mVs [95% CI, 0.72-3.14] [n = 8 studies]). Compared with men receiving finasteride, men treated with S repens had similar improvements in urinary tract symptom scores (WMD, 0.37 international Prostate Symptom Score points [scale range, 0-35] 1:95% CI, -0.45 to 1.19] [n =2 studiesl) and peak urine flow (WMD, -0.74 mL/s [95% CI, -1.66 to 0.18] [n = 2 studies]). Adverse effects due to S repens were mild and infrequent; erectile dysfunction was more frequent with finasteride (4.9%) than with S repens (1.1%; P < .001). Withdrawal rates in men assigned to placebo, S repens, or finasteride were 7%, 9%, and 11%, respectively. Conclusions.-The existing literature on S repens for treatment of BPH is limited in terms of the short duration of studies and variability in study design, use of phytotherapeutic preparations, and reports of outcomes. However, the evidence suggests that S repens improves urologic symptoms and flow measures. Compared with finasteride, S repens produces similar improvement in urinary tract symptoms and urinary flow and was associated with fewer adverse treatment events. Further research is needed using standardized preparations of S repens to determine its long-term effectiveness and ability to prevent BPH complications.
引用
收藏
页码:1604 / 1609
页数:6
相关论文
共 54 条
[1]  
[Anonymous], 1983, UROLOGIA
[2]  
[Anonymous], COMPTE REND THER PHA
[3]  
[Anonymous], 1983, UROLOGIA
[4]  
Barry MJ, 1997, JAMA-J AM MED ASSOC, V278, P2178
[5]   THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE [J].
BERRY, SJ ;
COFFEY, DS ;
WALSH, PC ;
EWING, LL .
JOURNAL OF UROLOGY, 1984, 132 (03) :474-479
[6]  
Boccafoschi C, 1983, Urologia, V50, P1257
[7]   Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials [J].
Boyle, P ;
Gould, AL ;
Roehrborn, CG .
UROLOGY, 1996, 48 (03) :398-405
[8]  
Braeckman J, 1997, EUR J CLIN RES, V9, P247
[9]   Phytotherapy for the prostate [J].
Buck, AC .
BRITISH JOURNAL OF UROLOGY, 1996, 78 (03) :325-336
[10]   TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH PHYTOSTEROLS [J].
CARBIN, BE ;
LARSSON, B ;
LINDAHL, O .
BRITISH JOURNAL OF UROLOGY, 1990, 66 (06) :639-641